Current Report Filing (8-k)
2019年2月15日 - 8:26PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
February 14, 2019
Frélii,
Inc.
|
(Exact
name of registrant as specified in its charter)
|
Nevada
|
|
333-107179
& 000-51210
|
|
980380519
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
2600
W. Executive Pkwy., Suite 500
Lehi, UT 84043
(Address
of Principal Executive
Offices)
(833) 437-3544
Registrant’s
telephone number, including area code
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[
]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
[ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
Frelii
appointed two physicians, Anthony R. Torres, M.D. and Susan H. Morelli M.D., to its Scientific Advisory Committee.
Dr.
Morelli and Dr. Torres will help Frelii accelerate and improve its work with pilot clinical trials, which will drive an increase
in the speed of learning of Frelii’s algorithms and AI platform. Their input will help address the challenges and opportunities
of delivering practical and accurate whole-genome sequencing solutions to the market.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Frélii, Inc.
|
|
|
Date:
February 14, 2019
|
By:
|
/s/
Ian Jenkins
|
|
Name:
|
Ian Jenkins
|
|
Title:
|
Chief Executive Officer
|
Frlii (CE) (USOTC:FRLI)
過去 株価チャート
から 5 2024 まで 6 2024
Frlii (CE) (USOTC:FRLI)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Frlii Inc (CE) (その他OTC): 0 recent articles
その他のFrelii, Inc.ニュース記事